Geode Capital Management LLC Raises Position in Curis, Inc. (NASDAQ:CRIS)

Geode Capital Management LLC raised its position in Curis, Inc. (NASDAQ:CRIS) by 27.3% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 83,129 shares of the biotechnology company’s stock after buying an additional 17,820 shares during the period. Geode Capital Management LLC owned about 0.98% of Curis worth $254,000 at the end of the most recent reporting period.

Separately, CM Management LLC boosted its stake in shares of Curis by 83.3% in the fourth quarter. CM Management LLC now owns 220,000 shares of the biotechnology company’s stock worth $673,000 after acquiring an additional 100,000 shares during the last quarter. Institutional investors own 29.97% of the company’s stock.

Curis Price Performance

CRIS opened at $2.41 on Friday. The firm has a market capitalization of $20.46 million, a price-to-earnings ratio of -0.31 and a beta of 3.51. The company’s 50 day simple moving average is $2.09 and its two-hundred day simple moving average is $3.18. Curis, Inc. has a 1-year low of $1.02 and a 1-year high of $16.93.

Curis (NASDAQ:CRIS) last announced its quarterly earnings data on Monday, March 31st. The biotechnology company reported ($1.25) EPS for the quarter, topping analysts’ consensus estimates of ($1.36) by $0.11. The firm had revenue of $2.70 million for the quarter, compared to the consensus estimate of $2.04 million. Curis had a negative return on equity of 923.37% and a negative net margin of 443.35%. On average, equities analysts anticipate that Curis, Inc. will post -7.12 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

CRIS has been the subject of several recent research reports. HC Wainwright reduced their price objective on Curis from $20.00 to $16.00 and set a “buy” rating for the company in a research note on Monday, March 31st. StockNews.com began coverage on shares of Curis in a report on Wednesday. They set a “hold” rating for the company.

Curis Company Profile

Curis, Inc, a biotechnology company, engages in the discovery and development of drug candidates for the treatment of human cancers in the United States. Its clinical stage drug candidates include Emavusertib, an oral small molecule IRAK4 kinase inhibitor, which is in a Phase 1/2 open-label, single arm expansion trial in patients with relapsed or refractory, or R/R, AML and high-risk myelodysplastic syndromes.